AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Accounts Receivables · Q4 FY2024 · quarter ended Dec 2024
Accounts receivables of €0 in Q4 FY2024
Q4 FY2024 accounts receivables was €0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
Currency unavailable · from the cash flow
No Accounts Receivables data reported for this period type.
Accounts Receivables vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.86M USD | +44.2% | — | 3.4% | |
| LTM Mar 2026 | $6.81M USD | +5438.2% | +253.5% | 81.4% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $0 USD | — | — | 0.0% |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +44.2% | +253.5% | 3.4% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.